Frost & Sullivan Publishes Update Coverage Report on Brainsway Ltd.

Frost & Sullivan Publishes Update Coverage Report on Brainsway Ltd.

PR Newswire

TEL AVIV, Israel, Nov. 27, 2018

Continued revenue growth based on the rental model; sufficient cash available in order to continue clinical plans; Expected breakeven in 2019; In light of the company's ability to maintain our expectations the target price has risen to 37.1 NIS

TEL AVIV, Israel, Nov. 27, 2018 /PRNewswire/ -- The TASE analysis project was launched in 2016 in order to raise investor awareness to TASE listed technology and life-science companies and the markets in which these companies operate, thus creating appropriate pricing and increasing the exposure of investors from Israel and abroad. Its goal is to encourage investments in these companies by improving understanding of these industries and companies in the market.

In order to maintain professional, independent and unbiased analysis, the companies signed an agreement with the TASE to receive the analysis services for an obligatory period of two years. The companies cannot withdraw from the project during this period. The analysis is funded by the companies surveyed with funding from the Chief Scientist and the TASE.

Summary of Highlights

On the 13th of November the company released its 3rd quarter report, below we highlight the main points of this report:

Good financial statistics that indicate the success of company sales using the rental model; sufficient cash funds to support the strategic plan of the company

Marketing approval for OCD patients represents positive testimony for the use of the company's clinical platform to treat additional indications

We expect the company to breakeven in 2019; the company is expected to continue its market penetration in the U.S.; 2019 will show increased sales in the U.S. market along with the completion of clinical experiments for additional indications

About the company - Brainsway Ltd. is an Israeli medical device firm focused on the development and commercialization of an H-coil helmet device for Deep Transcranial Magnetic Stimulation (dTMS). dTMS enables non-invasive activation of deep brain structures that can cover a broad range of brain disorders. The company has FDA market approval for Major Depressive Disorder, and wide reimbursement coverage for this indication. The company has recently received positive results in Obsessive Compulsive Disorder (OCD) patients, and will apply for market approval in the US for this indication. Approximately 15,000 patients were treated to date with Brainsway's device. Please click here (https://ww2.frost.com/research/equity-research/brainsway-ltd/)

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Contact us:  Start the discussion

For further information, please contact:

Kristi Cekani 
Corporate Communications - Frost & Sullivan, Europe
P: +39.02.4851.6133
E: Kristi.cekani@frost.com
http://www.frost.com

 

Voltar noticias em Inglês